Nodality is a next-generation biotechnology company dedicated to improving therapeutic drug development and advancing precision medicine as well as generating predictive and companion diagnostics.
Nodality's unique platform, Single Cell Network Profiling or SCNP, is designed to unlock the potential of transformative therapeutics. SCNP profiles signaling pathways and responses at the single cell level, generating new insight into disease biology and enabling better medicine. Only SCNP can provide network-level views of drug and target interactions in specific cells of interest including rare cells.
SCNP is covered by broad proprietary protections, with exclusive licenses to foundational patents from Stanford University.
Nodality partners with pharmaceutical and biotechnology companies to create competitive advantages by accelerating, optimizing, and de-risking clinical trials and facilitating companion diagnostic development. Nodality initially is focused on applying its technology to address unmet medical needs in autoimmune diseases, immunology and oncology including cancer immunotherapy.
Nodality's investors include Kleiner Perkins Caufield and Byers, TPG Ventures, Maverick Capital, Stanford University, Pfizer Venture Investments, and LabCorp.